USANA Health Sciences (NYSE:USNA) Shares Cross Above 200 Day Moving Average – Here’s What Happened

USANA Health Sciences, Inc. (NYSE:USNA)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $19.41 and traded as high as $21.40. USANA Health Sciences shares last traded at $21.15, with a volume of 144,191 shares changing hands.

Wall Street Analyst Weigh In

USNA has been the topic of a number of research analyst reports. Zacks Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, USANA Health Sciences currently has a consensus rating of “Reduce”.

USANA Health Sciences Trading Up 2.2%

The business has a fifty day simple moving average of $18.95 and a two-hundred day simple moving average of $19.41. The stock has a market cap of $390.43 million, a PE ratio of 45.00, a P/E/G ratio of 0.81 and a beta of 0.77.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The company had revenue of $250.22 million during the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, research analysts predict that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.

Insider Transactions at USANA Health Sciences

In other news, insider Joshua Foukas sold 3,791 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $19.82, for a total value of $75,137.62. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Brent Neidig sold 5,002 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 17,660 shares of company stock worth $336,579. Corporate insiders own 0.82% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC increased its stake in shares of USANA Health Sciences by 82.8% during the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company’s stock valued at $589,000 after purchasing an additional 9,894 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of USANA Health Sciences in the 1st quarter worth approximately $687,000. Russell Investments Group Ltd. boosted its position in shares of USANA Health Sciences by 31.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company’s stock worth $408,000 after purchasing an additional 3,198 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after buying an additional 646 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of USANA Health Sciences in the 2nd quarter worth approximately $422,000. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.